Sep 27, 2019 · QURE on StockCharts.com uniQure BV, a biopharmaceutical company, develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency, an orphan metabolic disease. uniQure N.V. (QURE) Stock Analysis & News | Seeking Alpha Get breaking news and analysis on uniQure N.V. (QURE) stock, price quote and chart, trading and investing tools. QURE | Stock Snapshot - Fidelity Apr 01, 2020 · Stock quote and company snapshot for UNIQURE NV (QURE), including profile, stock chart, recent news and events, analyst opinions, and research reports. QURE Stock Price & Charts | uniQure In depth view into QURE (uniQure) stock including the latest price, news, dividend history, earnings information and financials.
Description: E-Qure Corp is a US-based medical device company, which established for the purpose of acquiring certain of IP (intellectual property) assets pertaining to a wound healing device. The company owns IP assets which include wound healing device which is designed for wound treatment incorporating Bioelectrical Signal Therapy (BST Device). $EQUR Stock Technical Analysis | E-Qure Corp ...
©2020 StockTwits, Inc. All rights reserved. Market Data by Xignite and BATS BZX Real-Time Price. Securities products and services offered to self-directed Join Stocktwits for free stock discussions, prices, and market sentiment with millions of investors and traders. Stocktwits is the largest social network for finance. 23 Mar 2020 $BOLD $AVXS $QURE $ONCE $SGMO #AVRO #freeline. 3. 2. InsiderForms1/21 /20, 05:50 AM. VERTEX ONE ASSET MANAGEMENT INC. uniQure N.V. - Ordinary Shares (QURE). Today's Latest Price: $47.35 USD. 1.80 ( 3.95%). Updated Apr 6 2:26pm. Add QURE to Watchlist · Sign Up
Just prior to open and shortly after open I post momentum stocks to the trade chat room (and Twitter and Stocktwits if I have time). Some of my Favorite Set-Ups: (1) Momentum Stock Wash-Outs for Snap Back, (2) Bad News Wash-outs on Stocks with High Institutional Ownership, (3) Getting on the Right Side of a Trend Change and scaling in my Daily Biotech Pulse: Tonix Gets European Patent, EC Nod ... Mar 08, 2019 · Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on March 7) SGMO: Message Board for Sangamo Therapeutics, Inc ... 144275: Re: Dr. Bettina Cockroft, M.D., SVP and CMO at Sangamo Therapeutics, Inc., a genomic medicine company, discusses their approach to treating disease and why genomic medicines are so important to the future of medicine. StockTwits - 50 Best Websites 2010 - TIME Aug 25, 2010 · StockTwits is a by-product of all that financial chatter on Twitter. Think of the website as a social ticker — instead of tracking stock movements, it tracks the ongoing discussion around each stock. Find someone whose advice you trust, add them to a watch list and get a real-time stream of investing insight. The unvarnished info can be a
At the ProQR labs a novel technology was invented that has the potential to treat a large number of diseases that are currently untreatable. The Axiomer® platform technology is a novel way to correct RNA in the cells in patients and target mutations that cannot be treated with other technologies. Rocket Pharmaceuticals, Inc. (RCKT) Stock Forum ... Find the latest Rocket Pharmaceuticals, Inc. (RCKT) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. QURE Earnings Date, Forecast and Report (Uniqure) | MarketBeat Uniqure (NASDAQ:QURE) Earnings Information. Uniqure last announced its earnings data on March 2nd, 2020. The biotechnology company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by $0.19. The firm earned $2.63 million during the quarter, compared to analyst estimates of $1.76 million. Taking Requests: Amarin (NASDAQ:AMRN) | Seeking Alpha Jul 03, 2019 · Screen capture from Amarin's Vascepa site.. Amarin: Taking Requests. In the comments on my recent article on uniQure (NASDAQ:QURE), a reader …